Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enzo Biochem ( (ENZB) ) has provided an update.
On August 19, 2025, Enzo Biochem, Inc. held a special meeting of shareholders where they approved a merger agreement with Bethpage Parent, Inc. and its subsidiary. This merger involves Bethpage Merger Sub, Inc. merging with and into Enzo Biochem. The approval of the merger proposal negated the need for an adjournment proposal, and the merger is expected to close around August 20, 2025.
The most recent analyst rating on (ENZB) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Enzo Biochem stock, see the ENZB Stock Forecast page.
Spark’s Take on ENZB Stock
According to Spark, TipRanks’ AI Analyst, ENZB is a Neutral.
Enzo Biochem’s overall stock score is primarily impacted by its challenging financial performance and valuation issues due to declining revenues and profitability. However, the upcoming merger with Battery Ventures provides a positive outlook, offering a significant premium and a strategic path forward. Technical analysis shows potential short-term gains but also warns of overbought conditions.
To see Spark’s full report on ENZB stock, click here.
More about Enzo Biochem
Average Trading Volume: 363,513
Technical Sentiment Signal: Sell
Current Market Cap: $36.2M
Learn more about ENZB stock on TipRanks’ Stock Analysis page.